Tags : Psoriasis

Clinical Trials

BMS’ Deucravacitinib (BMS-986165) Demonstrate Superiority Over Amgen’ Otezla (apremilast) in

Shots: The P-III POETYK PSO-1 study involves assessing deucravacitinib (6mg, qd) vs PBO & Otezla (apremilast) in 666 patients with moderate to severe plaque psoriasis The trial met its co-1EPs & 2EPs demonstrating deucravacitinib was superior to Otezla (apremilast) in the patients reaching a PASI 75 and sPGA 0/1 @16wks. The overall safety profile of […]Read More

Clinical Trials

AbbVie Reports Results of SKYRIZI (risankizumab) in P-III LIMMitless Study

Shots: The P-III LIMMitless study is designed to evaluate the long-term safety & efficacy assessing risankizumab (150 mg q12wks.) continuous risankizumab with a loading dose in adults with moderate to severe plaque psoriasis. The analysis includes integrated data from five P-II & III studies (ultIMMa-1, ultIMMa-2, SustaIMM, IMMvent and NCT03255382) and the LIMMitless study Results: […]Read More

Biotech

Cumberland Pharmaceuticals’ RediTrex (methotrexate) Injection Receives the US FDA’s Approval

Shots: The approval of RediTrex is done post no. of communications with the FDA and several amendments to the NDA submitted to the FDA in late 2018 Cumberland to launch two injectable methotrexate product lines within the US targeted to treat active rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis RediTrex (methotrexate) Injection is targeted […]Read More

Biotech

Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health

Shots: Leo Pharma to get exclusive rights to develop & commercialize brodalumab in Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia for the treatment of moderate-to-severe psoriasis The sub-licensing agreement complements the ongoing licensing agreement b/w Leo & AstraZeneca to develop & commercialize brodalumab in Europe. Bausch Health has the rights to commercialize brodalumab through […]Read More